Cardiome pharma corp (CORV)
Income statement / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Revenue:
Product and royalty revenues

23,811

25,066

20,795

30,042

4,143

0

-

-

Licensing and other fees

197

190

115

0

368

463

453

65,234

Research collaborative fees (note 15)

-

-

-

-

-

326

1,052

830

Revenues

24,008

25,256

20,910

30,042

4,511

789

1,505

66,064

Cost of goods sold

6,776

6,310

6,587

10,027

936

0

-

-

Gross margin

17,232

18,946

14,323

20,015

3,575

789

-

-

Expenses:
Selling, general and administration

36,694

30,513

31,004

33,813

16,446

9,463

-

-

Research and development (note 15)

0

0

3,223

637

476

6,017

15,224

15,339

Amortization (notes 8 and 9)

3,517

2,984

2,177

2,150

649

1,229

1,095

1,154

Acquisition costs (note 4)

-

-

-

-

1,494

0

-

-

General and administration

-

-

-

-

-

-

11,549

12,875

Restructuring (note 16)

-

-

-

-

1,207

10,040

0

0

Gain on disposition of property and equipment

-

-

-

-

-

-

0

0

Loss on write-down of intangible assets

-

-

-

-

-

-

95

25

Operating Expenses

40,211

33,497

36,404

36,600

20,272

26,749

27,963

29,393

Operating loss

-22,979

-14,551

-22,081

-16,585

-16,697

-25,960

-26,458

36,671

Other expense:
Loss on extinguishment of long-term debt (note 11)

0

-1,402

0

-

20,834

11,218

0

0

Other expense on modification of long-term debt (note 11)

1,451

0

0

-

-

-

-

-

Interest expense

5,695

2,543

2,260

1,483

87

4,268

2,218

1,975

Other expense

511

348

175

136

-

-

-

-

Other expense (income)

-

-

-

-

633

-

-

-

Other income

-

-

-

-

-

650

756

803

Foreign exchange (gain) loss

1,188

-623

43

26

192

45

-

-

Other expense

-6,469

-4,916

-2,392

-1,593

21,572

7,645

-1,462

-1,172

Loss before income taxes

-29,448

-19,467

-24,473

-18,178

4,875

-18,315

-

-

Income tax expense (recovery) (note 18)

363

152

-11

49

102

0

-

-

Net loss

-29,811

-19,619

-24,462

-18,227

4,773

-18,315

-

-

Other comprehensive loss:
Foreign currency translation adjustments

791

-336

-449

-835

-227

0

-

-

Comprehensive loss

-29,020

-19,955

-24,911

-19,062

4,546

-18,315

-27,920

35,499

Loss per common share (note 16)
Basic

-0.90

-0.78

-1.34

-

-

-1.49

-

-

Diluted

-0.90

-0.79

-1.34

-

-

-1.49

-

-

Basic and diluted

-

-

-

-1.12

0.37

-

-0.46

0.58

Weighted average common shares outstanding (note 16)
Basic

33,192

25,255

18,198

-

12,769

12,254

61,125

60,813

Diluted

33,227

25,318

18,198

-

12,934

12,254

61,125

61,321

Basic and diluted

-

-

-

16,230

-

-

-

-